Cited 1 times in
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 박은향 | - |
dc.contributor.author | 이승태 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 김유나 | - |
dc.date.accessioned | 2023-08-09T07:01:25Z | - |
dc.date.available | 2023-08-09T07:01:25Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196034 | - |
dc.description.abstract | Objective: The RAD51 assay is a recently developed functional assay for homologous recombination deficiency (HRD) that reflects real-time HRD status. We aimed to identify the applicability and predictive value of RAD51 immunohistochemical expression in pre- and post-neoadjuvant chemotherapy (NAC) samples of ovarian high-grade serous carcinoma (HGSC). Methods: We evaluated the immunohistochemical expression of RAD51/geminin/γH2AX in ovarian HGSC before and after NAC. Results: In pre-NAC tumors (n=51), 74.5% (39/51) showed at least 25% of γH2AX-positive tumor cells, suggesting endogenous DNA damage. The RAD51-high group (41.0%, 16/39) showed significantly worse progression-free survival (PFS) compared to the RAD51-low group (51.3%, 20/39) (p=0.032). In post-NAC tumors (n=50), the RAD51-high group (36.0%, 18/50) showed worse PFS (p=0.013) and tended to present worse overall survival (p=0.067) compared to the RAD51-low group (64.0%, 32/50). RAD51-high cases were more likely to progress than RAD51-low cases at both 6 months and 12 months (p=0.046 and p=0.019, respectively). Of 34 patients with matched pre- and post-NAC RAD51 results, 44% (15/34) of pre-NAC RAD51 results were changed in the post-NAC tissue, and the RAD51 high-to-high group showed the worst PFS, while the low-to-low group showed the best PFS (p=0.031). Conclusion: High RAD51 expression was significantly associated with worse PFS in HGSC, and post-NAC RAD51 status showed higher association than pre-NAC RAD51 status. Moreover, RAD51 status can be evaluated in a significant proportion of treatment-naïve HGSC samples. As RAD51 status dynamically changes, sequential follow-up of RAD51 status might reflect the biological behavior of HGSCs. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Cystadenocarcinoma, Serous* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Geminin | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ovarian Neoplasms* / pathology | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Rad51 Recombinase | - |
dc.title | RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Kyeongmin Kim | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Yoo-Na Kim | - |
dc.contributor.googleauthor | Seung-Tae Lee | - |
dc.contributor.googleauthor | Eunhyang Park | - |
dc.identifier.doi | 10.3802/jgo.2023.34.e45 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A05760 | - |
dc.contributor.localId | A04627 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 36807748 | - |
dc.subject.keyword | Homologous Recombination | - |
dc.subject.keyword | Immunohistochemistry | - |
dc.subject.keyword | Neoadjuvant Chemotherapy | - |
dc.subject.keyword | Ovarian Cancer | - |
dc.subject.keyword | RAD51 recombinase | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 박은향 | - |
dc.contributor.affiliatedAuthor | 이승태 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | e45 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.34(4) : e45, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.